These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 8730728

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium.
    Davidenko JM, Cohen L, Goodrow R, Antzelevitch C.
    Circulation; 1989 Mar; 79(3):674-86. PubMed ID: 2917391
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.
    Aubert M, Osterwalder R, Wagner B, Parrilla I, Cavero I, Doessegger L, Ertel EA.
    Drug Saf; 2006 Mar; 29(3):237-54. PubMed ID: 16524323
    [Abstract] [Full Text] [Related]

  • 24. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
    Ducroq J, Printemps R, Guilbot S, Gardette J, Salvetat C, Le Grand M.
    J Pharmacol Toxicol Methods; 2007 Mar; 56(2):159-70. PubMed ID: 17604185
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Antiarrhythmic and electrophysiological effects of the novel KATP channel opener, rilmakalim, in rabbit cardiac cells.
    Riccioppo Neto F, Mesquita Júnior O, Olivera GB.
    Gen Pharmacol; 1997 Aug; 29(2):201-5. PubMed ID: 9251899
    [Abstract] [Full Text] [Related]

  • 27. Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres.
    Reichardt B, Konzen G, Hauswirth O.
    Naunyn Schmiedebergs Arch Pharmacol; 1990 May; 341(5):462-71. PubMed ID: 2164163
    [Abstract] [Full Text] [Related]

  • 28. Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.
    Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll EM, Lucchesi BR.
    Br J Pharmacol; 2001 Apr; 132(7):1493-500. PubMed ID: 11264243
    [Abstract] [Full Text] [Related]

  • 29. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre.
    Persson F, Andersson B, Duker G, Jacobson I, Carlsson L.
    Eur J Pharmacol; 2007 Mar 08; 558(1-3):133-43. PubMed ID: 17198698
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Electropharmacological effects of berberine on canine cardiac Purkinje fibres and ventricular muscle and atrial muscle of the rabbit.
    Riccioppo Neto F.
    Br J Pharmacol; 1993 Feb 08; 108(2):534-7. PubMed ID: 8448600
    [Abstract] [Full Text] [Related]

  • 32. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability.
    Roche M, Renauleaud C, Ballet V, Doubovetzky M, Guillon JM.
    J Pharmacol Toxicol Methods; 2010 Feb 08; 61(3):238-50. PubMed ID: 20117224
    [Abstract] [Full Text] [Related]

  • 33. Electrophysiological effects of ACC-9358, a novel class I antiarrhythmic agent, on isolated canine Purkinje fibers and ventricular muscle.
    Brown BS.
    J Pharmacol Exp Ther; 1989 Feb 08; 248(2):552-8. PubMed ID: 2918472
    [Abstract] [Full Text] [Related]

  • 34. Electrophysiological effects of tiracizin and its metabolites in dog cardiac Purkinje fibers.
    Németh M, Varró A, Papp JG.
    Gen Pharmacol; 1995 Jul 08; 26(4):793-8. PubMed ID: 7635254
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of new antiarrhythmic agent SS-68 on excitation conduction, electrical activity in Purkinje fibers and pulmonary veins: Assessment of safety and side effects risk.
    Bogus SK, Kuzmin VS, Abramochkin DV, Suzdalev KF, Galenko-Yaroshevsky PA.
    J Pharmacol Sci; 2017 Mar 08; 133(3):122-129. PubMed ID: 28325557
    [Abstract] [Full Text] [Related]

  • 39. Potassium channel openers antagonize the effects of class III antiarrhythmic agents in canine Purkinje fiber action potentials. Implications for prevention of proarrhythmia induced by class III agents.
    Kondo M, Tsutsumi T, Mashima S.
    Jpn Heart J; 1999 Sep 08; 40(5):609-19. PubMed ID: 10888381
    [Abstract] [Full Text] [Related]

  • 40. Inotropic and electrophysiological effects of AB--2, a new antiarrhythmic agent, on isolated cardiac preparations.
    Beresewicz A, Pytkowski B, Sedek G, Zdanowski K.
    Pol J Pharmacol Pharm; 1983 Sep 08; 35(3):223-32. PubMed ID: 6651921
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.